PMID- 38282878
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240131
IS  - 1642-395X (Print)
IS  - 2299-0046 (Electronic)
IS  - 1642-395X (Linking)
VI  - 40
IP  - 6
DP  - 2023 Dec
TI  - Efficacy and safety of upadacitinib for the treatment of moderate-to-severe 
      atopic dermatitis: a systematic review and meta-analysis.
PG  - 725-733
LID - 10.5114/ada.2023.133820 [doi]
AB  - INTRODUCTION: Upadacitinib, an oral selective-JAK1 inhibitor, has been used in 
      clinical trials to treat atopic dermatitis (AD). AIM: To evaluate the efficacy 
      and safety of upadacitinib in moderate-to-severe AD. MATERIAL AND METHODS: We 
      searched clinical trials from PubMed, Embase, Cochrane Library databases, and Web 
      of Science. All randomized controlled trials (RCTs) of upadacitinib treatment on 
      patients with moderate-to-severe AD were included. A meta-analysis was performed 
      using the fixed- or random-effects models to calculate pooled standard mean 
      differences or relative risks (SMD or RR, respectively). RESULTS: Compared with 
      the placebo group, our meta-analysis revealed that upadacitinib was related to a 
      significant decrease in Eczema Area and Severity Index (EASI) scores, and 
      pruritus numeric rating scale (NRS) scores. A higher response rate in 
      Investigator's Global Assessment (IGA) and EASI-75 were also detected in the 
      upadacitinib group. Although patients treated with upadacitinib experienced a 
      higher incidence of adverse events (AEs), these AEs were mild and tolerated. As 
      for serious adverse events (SAEs), there was no difference between the placebo 
      group and the upadacitinib group. CONCLUSIONS: This meta-analysis demonstrated 
      that upadacitinib is a safe and effective treatment for moderate-to-severe AD. 
      Further long-term trials are required for confirmation.
CI  - Copyright: (c) 2023 Termedia Sp. z o. o.
FAU - Huang, Yuanjie
AU  - Huang Y
AD  - Department of Dermatology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Cai, Limin
AU  - Cai L
AD  - Department of Dermatology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Wu, Xuerui
AU  - Wu X
AD  - Department of Dermatology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Chen, Chen
AU  - Chen C
AD  - Department of Dermatology, The First Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240108
PL  - Poland
TA  - Postepy Dermatol Alergol
JT  - Postepy dermatologii i alergologii
JID - 101168357
PMC - PMC10809830
OTO - NOTNLM
OT  - atopic dermatitis
OT  - meta-analysis
OT  - upadacitinib
COIS- The authors declare no conflict of interest.
EDAT- 2024/01/29 06:43
MHDA- 2024/01/29 06:44
PMCR- 2023/12/01
CRDT- 2024/01/29 04:09
PHST- 2024/01/29 06:44 [medline]
PHST- 2024/01/29 06:43 [pubmed]
PHST- 2024/01/29 04:09 [entrez]
PHST- 2023/12/01 00:00 [pmc-release]
AID - 52085 [pii]
AID - 10.5114/ada.2023.133820 [doi]
PST - ppublish
SO  - Postepy Dermatol Alergol. 2023 Dec;40(6):725-733. doi: 10.5114/ada.2023.133820. 
      Epub 2024 Jan 8.